The official French guidelines to protect patients with cancer against SARS-CoV-2 infection

You, Benoît; Ravaud, Alain; Canivet, Anne; Ganem, G.; Giraud, P.; Guimbaud, Rosine; Kaluzinski, Laure; Krakowski, I.; Mayeur, Didier; Grellety, Thomas; Lotz, Jean Pierre

doi:10.1016/s1470-2045(20)30204-7

Cited by 165 publications

(181 citation statements)

References 1 publication

Supporting

Mentioning

169

Contrasting

Unclassified

Order By: Relevance

“…Practice of oncology in France was not different than that in China and Italy, but some French societies have recently issued formal guidelines for the management of specific types of malignancy. All these propositions meet the recommendations published on the 14th of March by a group of French experts solicited by the president of Public Health Council on SARS-CoV-2 infection and solid cancers (77,78).…”

Section: The French Experiencementioning

confidence: 68%

Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence

Moujaess

Kourié

Ghosn

2020

Critical Reviews in Oncology/Hematology

185

192

View full text Add to dashboard Cite

The novel coronavirus, also known as SARS-Cov-2 or COVID-19 has become a worldwide threat and the major healthcare concern of the year 2020. Cancer research was directly affected by the emerging of this disease. According to some Chinese studies, cancer patients are more vulnerable to COVID-19 complications. This observation led many oncologists to change their daily practice in cancer care, without solid evidence and recommendations. Moreover, the COVID-19 manifestations as well as its diagnosis are particular in this special population. In this review paper we expose the challenges of cancer management in the era of SARS-CoV-2, the epidemiological, clinical, pathological and radiological characteristics of the disease in cancer patients and its outcomes on this population. Finally, we focus on strategies that are followed in cancer management with review of national and international guidelines. J o u r n a l P r e -p r o o f electronic search of the literature was conducted in the PubMed database until the 5th of April 2020. The following keywords with Boolean operators were used 'covid-19', 'novel coronavirus'and 'SARS-CoV-2' in combination with 'cancer', 'neoplasm', 'oncology' and 'malignancy'. A total of 223 articles were extracted. We included articles in English as well as articles in French because we are familiar with this language. Abstracts in English of articles in Chinese language were also J o u r n a l P r e -p r o o f 3 included. Duplicated articles and articles that were published before the era of SARS-Cov-2 (i.e., before December 2019) were excluded. Titles and abstracts of retrieved articles were screened for eligibility, and then entire texts were analyzed and 88 papers that respond to our objectives were included in this review. Our work is summarized in the PRISMA diagram below. ResultsOut of 88 articles, six were in French language and 19 were in Chinese language with English abstracts. Most of the papers consisted of short editorials, letters, correspondence or comments.Ten Cohort studies were identified (retrospective, prospective or cross-sectional analysis) as well as 9 case reports and one case series. Only four of the cohort studies exclusively included cancer patients. Of note, all cohort studies were conducted in China. Most of the reported cases originated from China and Italy.59% of the published papers originated from China and Italy (52 of 88). Seven works were multinational and the majority of them were multicontinental, issued in collaboration between researchers from Asia, Europe and the Americas. We identified one article originating from each of the following countries: Canada, India, Singapore, Spain and Saudi Arabia. The pie chart below

show abstract

Section: The French Experiencementioning

confidence: 68%

Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence

Moujaess

Kourié

Ghosn

2020

Critical Reviews in Oncology/Hematology

185

192

View full text Add to dashboard Cite

show abstract

“…Kokorovic et al Managing prostate cancer during COVID-19 6 © 2020 Canadian Urological Association chemotherapy within 1 month are at higher risk for severe illness 2 . Chemotherapy administration is also associated with more intense resource utilization and risk exposure.…”

Section: Cuaj -Consensus Statementmentioning

confidence: 99%

“…In addition, intubation is a procedure that carries high risk of spreading the virus to members of the healthcare team present in the operating room. These complexities in cancer care have resulted in the release of several guidelines regarding management of oncology patients during the COVID-19 era [5][6][7][8][9] . Two recent Canadian Urological Association (CUA) publications outline recommendations on surgical Screening and detection 1.…”

Section: Introductionmentioning

confidence: 99%

A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association

Kokorovic

Hotte

et al. 2020

CUAJ

View full text Add to dashboard Cite

triaging and the use of systemic therapies in genitourinary malignancies 7,9 . The purpose of this publication is to provide a multidisciplinary framework focused on prostate cancer management in the setting of the COVID-19 global pandemic within the Canadian context. General principles1. This consensus statement is a guide to help physicians manage prostate cancer during the acute phase of a pandemic. Treatment prioritization must take into account regional differences in infection rates, resource capacity and mitigation efforts. The current pandemic has had a widespread reach across all Canadian communities, but we recognize that the degree of impact varies, and that provincial and institutional policies are not uniform. Physicians must continue to monitor a continuously evolving situation and make adjustments to clinical decisions as deemed appropriate. The risk of serious morbidity resulting from SARS-CoV-2 infection may outweigh thecompeting risk of prostate cancer in many men. Observation of prostate cancer in carefully selected patients does not increase long-term mortality 10,11 , and therefore shortterm treatment delays are unlikely to lead to disease progression and worse outcomes . All management decisions should be based on this core principle. Appropriate patient counseling and shared decision making is strongly encouraged.Men diagnosed with prostate cancer have increased anxiety and psychological distress 12,13 . This will undeniably become amplified in the setting of a global health crisis. Despite resource restrictions and changes in treatment recommendations, physicians must continue to address the needs of patients and involve them in the decision-making process. This approach may decrease patient anxiety levels and improve outcomes once regular practice resumes. Prioritization must be given to limiting exposures of patients and healthcare workers toSARS-CoV-2. Implementation of telehealth visits significantly reduces the risk of infection among frontline personnel and patients, but also preserves critically needed hospital resources. For these reasons, telehealth visits are strongly encouraged. In-person consultations should be limited to men with new symptoms, those requiring a physical examination and for the evaluation and management of treatment-related serious adverse events. In men who require an in-person assessment, consideration should be given to not repeating visits when two specialists are consulted, nor when pre-operative assessment is needed. The healthcare provider should coordinate their needs to minimize patient's visits. CUAJ -Consensus Statement Kokorovic et al Managing prostate cancer during COVID-193

show abstract

“…The British Thoracic Society (BTS) recently published recommendations on coronavirus disease 2019 (COVID-19) and lung cancer/mesothelioma [3], and the French Haut Conseil de la Santé Publique (HCSP) published on cancer in general [4,5]. This letter describes the viewpoint of the authors on these general recommendations (not always in agreement!)…”

mentioning

confidence: 99%

“…and tries to translate them into practical advice for clinicians (note: some may not be feasible due to reimbursement issues), starting with the current standard care. In all patients, we suggest video consultation is used as much as possible instead of face-to-face consultation [3,5].…”

mentioning

confidence: 99%

Cancer in the time of COVID-19: expert opinion on how to adapt current practice

et al. 2020

View full text Add to dashboard Cite

The official French guidelines to protect patients with cancer against SARS-CoV-2 infection

Cited by 165 publications

References 1 publication

Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence

Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence

A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association

Cancer in the time of COVID-19: expert opinion on how to adapt current practice

Contact Info

Product

Resources

About